Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,182 across all filing types
Latest filing 2022-01-25 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice informing about the scheduling of an earnings call for Quarter III FY 2022. It references the regulatory requirement under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and states that transcripts of the call will be filed later. The document does not contain any financial data or results itself, nor does it include a transcript or detailed financial report. It is essentially an announcement about the upcoming earnings call event. Given the document length (1460 characters) and content, it fits best as a Regulatory Filing (RNS) since it is a regulatory announcement without substantive financial data or transcript content.
2022-01-25 English
Earnings Call for Quarter - III, FY 2022 is scheduled on Friday, February 4, 2022 at 18:30 hrs (IST).
Regulatory Filings Classification · 95% confidence The document is a short notice informing about the scheduling of an earnings call for Quarter III FY 2022. It references the SEBI regulations for disclosure but does not contain any financial data or transcript itself. The document length is only 1468 characters, which is quite short and fits the pattern of an announcement rather than a full report or transcript. It explicitly states that transcripts will be filed later, indicating this is a notification of an upcoming event rather than the event content. Therefore, it should be classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not contain the actual earnings release or call transcript.
2022-01-25 English
Board Meeting — Financial Results/Other business matters
Regulatory Filings Classification · 95% confidence The document is a short notice dated January 19, 2022, addressed to stock exchanges (BSE and NSE) announcing a forthcoming Board of Directors meeting scheduled for February 3, 2022. The purpose of the meeting is to consider and take on record the unaudited financial results for the quarter and nine months ended December 31, 2021. The document is brief (1375 characters) and serves as an announcement of an upcoming event rather than containing any financial data or results itself. It does not contain actual financial statements or detailed analysis, nor is it a transcript or presentation. It is a regulatory announcement pursuant to SEBI regulations about the board meeting date and agenda. According to the classification rules, such short notices announcing meetings or report publication dates fall under Regulatory Filings (RNS) rather than Interim Reports (IR) or Earnings Releases (ER).
2022-01-19 English
LUPIN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2022 ,inter alia, to consider and approve LUPIN LTD. has informed BSE that the ....
Regulatory Filings Classification · 95% confidence The document is a short notice dated January 19, 2022, addressed to stock exchanges, informing about a forthcoming Board of Directors meeting scheduled for February 3, 2022. The purpose of the meeting is to consider and take on record the unaudited financial results for the quarter and nine months ended December 31, 2021. The document does not contain any financial data or results itself, only an announcement of the meeting where such results will be discussed. The length is only 1368 characters, which is very short and consistent with an announcement rather than a full report. According to the rules, such a notice is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about an upcoming event related to financial results, not the results themselves or a detailed report.
2022-01-19 English
Lupin Signs First Partnership Agreement with Foncoo for China.
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a partnership agreement between Lupin Limited and Shenzhen Foncoo Pharmaceutical Co. Ltd. It is addressed to stock exchanges and references compliance with SEBI regulations for disclosure. The content focuses on the partnership details and company background, without any financial statements, earnings data, or regulatory filings. It is not an annual report, earnings release, or management discussion. It is a corporate announcement about a business partnership, which fits best under Capital/Financing Update (CAP) as it relates to strategic business development and partnership agreements that can impact company growth and capital structure indirectly. The document length is 5872 characters, which is consistent with a press release rather than a full report. Therefore, the classification is CAP with high confidence.
2022-01-19 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a new partnership agreement between Lupin Limited and Shenzhen Foncoo Pharmaceutical Co. Ltd. It is addressed to stock exchanges and references compliance with SEBI regulations for disclosure. The content focuses on the partnership details, company background, and contact information. There are no financial statements, quarterly or annual results, or detailed financial data. The document is not a report but a corporate announcement about a business development. Therefore, it fits best under the category of Capital/Financing Update (CAP), as it relates to a strategic partnership which can be considered a financing or capital-related update rather than a full financial report or regulatory filing.
2022-01-19 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.